Research Interests

Our group long term interest is to develop new biopharmaceutical based drugs with enhanced immunomodulatory, anti-inflammatory and/or wound-healing activities by using structure activity relationships studies in order to use them in a broad-range of medical applications. Our scientific career interest is to develop a molecule that has the potential to shift the balance of inflammation by promoting anti-infective immune mechanisms and suppressing harmful inflammation.

AMPs activate the innate immune system, which provides shorter, non-specific wide spectrum protection to the host without any memory. On the contrary, vaccines activates the adaptive immune system that provides long-term single pathogen protection with memory.

Cationic host defense peptides (HDPs) are regarded as one of the most promising alternative infectious disease therapies. HDPs, formerly known as antimicrobial peptides (AMPs), are evolutionary conserved, hydrophobic and amphipathic short (<50 amino acids) cationic molecules with a net charge of +2 to +9. HDPs are ubiquitous defence biomolecules in nature; they are produced in all organisms ranging from plants and insects to humans, and comprise an integral component of innate defences against infections. We previously create a large number of peptide variants through structure based evolutionary guided method, sequence scrambling, truncations and systematic modifications of peptide sequence, and investigated their ability to clear infections (S.aureus and P.aeruginosa) both in vitro and in vivo. While hundreds of peptides have been virtually designed (ie in silico), only a few have been actually synthesized to date.

There is still a large pool of broader variety of peptides with excellent predicted antimicrobial and/or immunomodulatory activity that remains to be unconfirmed.